|
🦁
|
Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib
I. Muller,
A. D. de Langen,
R. Honeywell,
E. Giovannetti,
G. Peters
|
5 |
2016 |
5
🦁
|
|
🦁
|
Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib
I. Muller,
A. D. de Langen,
E. Giovannetti,
G. Peters
|
4 |
2017 |
4
🦁
|
|
🐜
|
Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools
14 auth.
E. Giovannetti,
P. Zucali,
Y. Assaraf,
N. Funel,
Maria Gemelli,
M. Stark,
Erik Thunnissen,
Z. Hou,
I. Muller,
Eduard A. Struys,
...
M. Perrino,
Gerrit Jansen,
L. Matherly,
Godefridus J. Peters
|
4 |
2017 |
4
🐜
|
|
🐜
|
Patient-derived oral mucosa organoids as an in vitro model for methotrexate induced toxicity in pediatric acute lymphoblastic leukemia
11 auth.
E. Driehuis,
N. Oosterom,
S. Heil,
I. Muller,
M. Lin,
S. Kolders,
...
G. Jansen,
R. de Jonge,
R. Pieters,
H. Clevers,
M. V. D. van den Heuvel-Eibrink
|
4 |
2020 |
4
🐜
|
|
🐜
|
Identification of Metabolic Biomarkers in Relation to Methotrexate Response in Early Rheumatoid Arthritis
8 auth.
H. Gosselt,
I. Muller,
G. Jansen,
M. van Weeghel,
F. Vaz,
J. Hazes,
...
S. Heil,
R. de Jonge
|
4 |
2020 |
4
🐜
|
|
🦁
|
Computational comparison of common event-based differential splicing tools: practical considerations for laboratory researchers
10 auth.
I. Muller,
Stijn Meijers,
P. Kampstra,
Steven van Dijk,
Michel van Elswijk,
Marry Lin,
...
A. Wojtuszkiewicz,
G. Jansen,
R. de Jonge,
J. Cloos
|
3 |
2021 |
3
🦁
|
|
🦁
|
Association of altered folylpolyglutamate synthetase pre-mRNA splicing with methotrexate unresponsiveness in early rheumatoid arthritis
10 auth.
I. Muller,
Marry Lin,
W. Lems,
M. T. ter Wee,
A. Wojtuszkiewicz,
M. Nurmohamed,
...
J. Cloos,
Y. Assaraf,
G. Jansen,
R. de Jonge
|
3 |
2020 |
3
🦁
|
